Abstract
Extracellular ATP, released upon microbial infection, cell damage, or inflammation, acts as an alert signal toward immune cells by activating P2 receptors. The nucleotide causes microvesicle (MV) shedding from immune and nonimmune cells. Here, we show that IL-18 associates with MVs shed by human ex vivo macrophages upon P2X receptor stimulation. MV shedding was potently induced by ATP and by the P2X7 agonist 3'-benzoylbenzoyl adenosine 5'-triphosphate, while it was greatly reduced by P2X irreversible inhibitor-oxidized ATP and by the specific P2X7 inhibitors KN-62, A-740003, and A-438079. Peculiarly, the P2X7 subtype was highly present in the MVs, while on the contrary the P2X3 and P2X4 subtypes were almost absent. The Ca(2+) ionophore A23187 mimicked the effect of 3'-benzoylbenzoyl adenosine 5'-triphosphate suggesting that an intracellular Ca(2+) increase was sufficient to evoke MV shedding. Caspase inhibitors Ac-YVAD-CMK or Z-YVAD-CMK did not block the cleavage of MV-associated pro-IL-18. Pro-IL-18 formation in macrophages did not require pretreatment of cells with LPS, as the procytokine was already present in unprimed macrophages and did not decrease by incubating cells with the LPS-binding antibiotic polymyxin B nor with the TLR-4 intracellular inhibitor CLI-095. These data reveal a nucleotide-based mechanism responsible for the shedding of MV to which IL-18 is associated.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives
-
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
-
Acetamides / pharmacology
-
Adenosine Triphosphate / analogs & derivatives
-
Adenosine Triphosphate / pharmacology
-
Anti-Bacterial Agents / pharmacology
-
Calcimycin / pharmacology
-
Calcium Ionophores / pharmacology
-
Cell-Derived Microparticles / immunology*
-
Cell-Derived Microparticles / metabolism
-
Humans
-
Interleukin-18 / immunology*
-
Interleukin-18 / metabolism
-
Lipopolysaccharides / pharmacology*
-
Macrophages / immunology*
-
Macrophages / metabolism
-
Polymyxin B / pharmacology
-
Protein Precursors / immunology*
-
Protein Precursors / metabolism
-
Purinergic P2X Receptor Agonists / pharmacology
-
Purinergic P2X Receptor Antagonists / pharmacology
-
Pyridines / pharmacology
-
Quinolines / pharmacology
-
Receptors, Purinergic P2X4 / immunology*
-
Receptors, Purinergic P2X4 / metabolism
-
Receptors, Purinergic P2X7 / immunology*
-
Receptors, Purinergic P2X7 / metabolism
-
Sulfonamides / pharmacology
-
Tetrazoles / pharmacology
-
Toll-Like Receptor 4 / immunology*
-
Toll-Like Receptor 4 / metabolism
Substances
-
(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide)
-
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine
-
Acetamides
-
Anti-Bacterial Agents
-
Calcium Ionophores
-
Interleukin-18
-
Lipopolysaccharides
-
Protein Precursors
-
Purinergic P2X Receptor Agonists
-
Purinergic P2X Receptor Antagonists
-
Pyridines
-
Quinolines
-
Receptors, Purinergic P2X4
-
Receptors, Purinergic P2X7
-
Sulfonamides
-
TLR4 protein, human
-
Tetrazoles
-
Toll-Like Receptor 4
-
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate
-
Calcimycin
-
3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate
-
KN 62
-
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
-
Adenosine Triphosphate
-
Polymyxin B